Category: 3. Business

Speakers from financial institutions, NGOs, government, and industry highlighted how biodiversity protection, community engagement, and energy development can be mutually reinforcing when built into project design and policy frameworks.

Examples ranged from solar projects in France that integrate wetland restoration, eco-grazing, and citizen investment, to marine wind farms in the North Sea linked to long-term marine conservation funding. In Uzbekistan, solar developers are protecting tortoise habitats and partnering with local herders to manage grazing. In Qinghai Province, China, large-scale PV parks are reversing desertification while supporting ecological animal husbandry.

Industry actors like TotalEnergies are scaling agro-photovoltaic models that combine renewable energy generation with sustainable farming. Policymakers and financial institutions, including the European Bank for Reconstruction and Development (EBRD) and the International Renewable Energy Agency (IRENA), underscored the role of strong policy frameworks, financing incentives, and capacity building to scale these approaches globally. 

Ecowende is developing the Netherlands’ most ecological offshore wind farm to date—powering 3% of national demand while enhancing North Sea biodiversity—through an innovative, research-driven and collaborative approach supported by IUCN’s Biodiversity Advisory Team, which provides independent review and recommendations on biodiversity goals and targets.

From regulatory tools to community partnerships, the session highlighted that the energy transition can—and must—deliver measurable gains for biodiversity and people.

The session was moderated by Qiulin Liu from IUCN and speakers included Adonai Herrera-Martínez from EBRD, Aonghais Cook from The Biodiversity Consultancy, Dr. Ma Hao from the Qinghai Provincial Development and Reform Commission, Jinlei Feng from IRENA, Karen Westley from Ipieca, Libby Sandbrook from Fauna & Flora, Sophie Depraz from Ipieca, Steven Dickinson from TotalEnergies, Yu Miao from SPIC Huanghe Hydropower Development Co., Ltd., and Zhang Jiali from the China Renewable Energy Engineering Institute (CREEI). 

Omvoh now offers patients a simplified maintenance experience with one monthly injection, replacing the previous two-injection regimen

 Omvoh single-injection dosing will be available for U.S. patients in early 2026

This is the third FDA approval for Omvoh this year, following approvals for Crohn’s disease and a citrate-free formulation

INDIANAPOLIS, Oct. 27, 2025 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved a single-injection, once-monthly maintenance regimen (200 mg/2 mL) of Omvoh (mirikizumab-mrkz) for subcutaneous use in adults with moderately to severely active ulcerative colitis (UC).

“In clinical practice, we see that simplifying maintenance treatment can make a difference in the overall patient experience,” said Miguel Regueiro, M.D., board-certified gastroenterologist specializing in inflammatory bowel disease. “A single monthly injection of Omvoh gives patients a regimen that’s easier to manage alongside the unpredictability of living with ulcerative colitis.”

The Omvoh single-injection, citrate-free maintenance dose will be available in the U.S. via prefilled pen or prefilled syringe in early 2026. The U.S. approval follows the recent European Union authorization of Omvoh for single-injection maintenance dosing for UC.

“People living with the constant discomfort and disruption caused by the symptoms of ulcerative colitis need treatments that offer the potential to achieve lasting remission and a convenient dosing option that fits easily into their lives,” said George Salem, M.D., director of Crohn’s and Colitis Center at OU HEALTH. “With this approval, patients who respond to induction therapy with Omvoh can continue maintenance therapy with the convenience of just one injection each month — delivering the same proven results with fewer injections.”

The single-injection approval is based on results from a Phase 1 study comparing one 200 mg/2 mL subcutaneous injection to two 100 mg/1 mL injections in participants. The study confirmed that Omvoh single-injection is bioequivalent to the previously approved two-injection regimen.¹ Treatment with Omvoh for ulcerative colitis starts with 300-mg IV infusions every four weeks, for a total of three infusions, and at Week 12 transitions to subcutaneous self-injection every four weeks for maintenance treatment.

“At Lilly, we are committed to supporting people living with IBD by delivering meaningful clinical outcomes and continuing to improve their treatment experience,” said Ashley Diaz-Granados, senior vice president of U.S. Immunology at Lilly. “Building on the introduction of a citrate-free formulation of Omvoh earlier this year, this approval further delivers on our commitment by providing patients the same outcomes in a single-injection maintenance regimen that fits more seamlessly into their lives.”

Omvoh is approved in the U.S. for the treatment of moderately to severely active UC and moderately to severely active Crohn’s disease in adults and has been approved in 45 countries around the world. Through Lilly Support Services™, Lilly offers a patient support program including co-pay assistance for eligible, commercially insured patients.

INDICATIONS AND SAFETY SUMMARY

Omvoh^® (ahm-VOH) is a medicine used to treat

• adults with moderately to severely active ulcerative colitis
• adults with moderately to severely active Crohn’s disease

It is not known if Omvoh is safe and effective in children under 18 years of age.

Warnings – Omvoh can cause serious side effects including:

Serious allergic reactions: Omvoh may cause serious allergic reactions that may need to be treated in a hospital and may be life-threatening. Do not use Omvoh if you have had a serious allergic reaction to mirikizumab-mrkz or any of the ingredients in Omvoh. See the Medication Guide that comes with Omvoh for a list of ingredients. Stop using Omvoh and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction:

• fainting, dizziness, feeling lightheaded
• swelling of your face, eyelids, lips, mouth, tongue, throat, or trouble swallowing
• trouble breathing, throat tightening, or wheezing
• chest tightness
• fast heartbeat or pounding in your chest
• severe itching, hives, or redness all over your body
• sweating

Infections: Omvoh may lower the ability of your immune system to fight infections and may increase your risk of infections. If you have an infection, your healthcare provider should not start treatment with Omvoh until your infection is gone. Before starting treatment with Omvoh, your healthcare provider should assess you for tuberculosis (TB). If you are at risk for TB, you may be treated with medicine for TB before you begin treatment with Omvoh. Your healthcare provider should watch you closely for signs and symptoms of TB while you are being treated with Omvoh and after treatment.

Before starting Omvoh, tell your healthcare provider if you think you have an infection or have symptoms of an infection, such as:

• fever, sweating, or chills
• muscle aches and pain
• cough or shortness of breath
• blood in your mucus (phlegm)
• flu-like symptoms
• headache
• warm, red, or painful skin or sores on your body
• diarrhea or stomach pain
• weight loss
• nausea or vomiting
• pain during urination

After starting Omvoh, tell your healthcare provider right away if you have any symptoms of an infection.

Liver Problems: Omvoh may cause liver problems. Your healthcare provider should do blood tests to check your liver enzyme and bilirubin levels before treatment, during, and after treatment with Omvoh. Your healthcare provider may hold or stop treatment if needed. Tell your healthcare provider right away if you develop any signs and symptoms of liver problems, including:

• unexplained rash
• nausea
• vomiting
• stomach-area (abdominal) pain
• feeling tired
• loss of appetite
• yellowing of the skin or the whites of your eyes
• dark urine

Common side effects

The most common side effects of Omvoh in people treated for ulcerative colitis include:

• upper respiratory infections
• injection site reactions
• joint pain
• rash
• headache
• herpes viral infections

The most common side effects of Omvoh in people treated for Crohn’s disease include:

• upper respiratory infections
• injection site reactions
• headache
• joint pain
• elevated liver blood tests

These are not all the possible side effects of Omvoh.

Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before you use Omvoh, review these questions with your doctor:

• Are you being treated for an infection?
• Do you have an infection that does not go away or keeps coming back?
• Do you have TB or have you been in close contact with someone with TB?
• Do you have any possible symptoms of an infection such as fever, chills, muscle aches, cough, shortness of breath, runny nose, sore throat, or pain during urination?

Tell your doctor about all your medical conditions, including if:

• You have a history of serious allergic reaction to Omvoh, any infections or liver problems.
• You need any vaccines or have had one recently. Medicines that interact with the immune system may increase your risk of getting an infection after receiving live vaccines. You should avoid receiving live vaccines right before, during or right after treatment with Omvoh. Tell your healthcare provider that you are taking Omvoh before receiving a vaccine.
• You are pregnant, or plan to become pregnant. It is not known if Omvoh will harm your unborn baby. There will be a pregnancy registry to collect information about women who are exposed to Omvoh during pregnancy. If you become pregnant while taking Omvoh, you are encouraged to report your pregnancy to Eli Lilly and Company at 1-800-545-5979.
• You are breastfeeding or plan to breastfeed. It is not known if Omvoh passes into your breastmilk.
• You take prescription or over-the-counter medicines, vitamins, or herbal supplements.

How to take
Follow your healthcare provider’s instructions for using Omvoh. You will receive your first 3 doses of Omvoh through a vein in your arm (intravenous infusion) in a healthcare facility by a healthcare provider every 4 weeks. Each infusion will last about 30 minutes (for ulcerative colitis) or about 90 minutes (for Crohn’s disease). After induction, you will continue to receive Omvoh maintenance doses as self-injections under the skin (subcutaneous injection) every 4 weeks. For these injections, Omvoh is available as prefilled pens or prefilled syringes. (If taking Omvoh for Crohn’s disease, you will need two injections to complete your dose, using either two prefilled pens or two prefilled syringes.) If you give injections at home, you should be trained on the correct way to prepare and inject Omvoh. Do not try to inject Omvoh yourself until you or your caregiver have been shown how to inject. Read the detailed Instructions for Use about how to use and dispose of Omvoh the correct way.

Learn more
Omvoh is a prescription medicine. During induction, Omvoh is available as a single-dose vial for intravenous infusion containing 300 mg/15 mL that is administered in a healthcare facility.

During maintenance, Omvoh is available as:

• For ulcerative colitis: one 200 mg/2 mL prefilled pen or prefilled syringe.
• For Crohn’s disease: one 100 mg/mL prefilled pen or prefilled syringe and one 200 mg/2 mL prefilled pen or prefilled syringe.

For more information, call 1-800-545-5979 or go to omvoh.lilly.com.

This summary provides basic information about Omvoh but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your doctor. Be sure to talk to your doctor or other healthcare provider about Omvoh and how to take it. Your doctor is the best person to help you decide if Omvoh is right for you.

MR CON BS 24OCT2025

Omvoh^® and its delivery device base are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

About Omvoh
Omvoh (mirikizumab-mrkz) is an interleukin-23p19 (IL-23p19) antagonist indicated for the treatment of moderately to severely active ulcerative colitis and Crohn’s disease in adults. Omvoh selectively targets the p19 subunit of IL-23 and inhibits the IL-23 pathway. Inflammation due to over-activation of the IL-23 pathway plays a critical role in the pathogenesis of inflammatory bowel disease.²

Omvoh and its delivery device base are trademarks owned by Eli Lilly and Company.

About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer’s disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY

CMAT-02499 10/2025 © Lilly USA, LLC 2025. ALL RIGHTS RESERVED. 

Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company’s or their rights thereto. We do not intend the use or display of other companies’ trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Omvoh (mirikizumab-mrkz) as a treatment for people with moderate to severe ulcerative colitis and moderate to severe Crohn’s disease and reflects Lilly’s current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with study results to date, that Omvoh will receive additional regulatory approvals, or that Omvoh will be commercially successful. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly’s expectations, see Lilly’s Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

References
¹ Otani Y, et al. One subcutaneous injection of mirikizumab is bioequivalent to two subcutaneous injections: results from a pharmacokinetic comparability study in healthy participants. 2025 United European Gastroenterology Week. October 4-7, 2025.
² Omvoh. Prescribing Information. Lilly USA, LLC. 

Refer to:        Kelly Hoffman; [email protected]; 765-736-2555 (Lilly media)
                       Michael Czapar; [email protected]; 317-617-0983 (Investors)

SOURCE Eli Lilly and Company

Percutaneous transseptal mitral valve replacement (TMVR) using the SAPIEN M3 system effectively reduced mitral regurgitation (MR) with low rates of complications and mortality in patients who were not candidates for conventional surgery or transcatheter edge-to-edge repair (TEER), according to results of the ENCIRCLE trial presented at TCT 2025 and simultaneously published in The Lancet.

The trial involved a total of 287 patients from the U.S., Canada, Europe, Israel and Australia who had MR ≥3+, NYHA Class ≥II, and were unsuitable for surgery or TEER due to clinical, anatomic or technical considerations. The balloon-expandable, dedicated SAPIEN M3 mitral transcatheter heart valve was implanted in each patient and follow-up was conducted at 30 days, six months and one year.

In overall findings, the primary endpoint – the composite of all-cause mortality and rehospitalization for heart failure at one year compared to a pre-specified performance goal of 45% – was 25.2%. All-cause death and heart failure hospitalization rates were 13.9% and 16.7%, respectively. Additionally, improvements in MR grade were observed across all patients, with more than 95% having ≤1+ total MR at 30 days and one year. Researchers also noted the TMVR system had a procedural safety profile similar to TEER and that patients experienced clinically meaningful and durable improvements in symptoms and quality of life.

“Percutaneous transseptal TMVR had a low mortality rate while providing a significant reduction in [MR] severity and providing meaningful and durable improvements in functional status and quality of life,” said David Daniels, MD. “These findings will help guide clinical practice by providing an alternative treatment option for patients who are not suitable for conventional surgery or TEER procedures.”

Additionally, Daniels and colleagues say their findings could allow for “future reintervention with percutaneous transseptal mitral valve-in-valve implantation in the event of structural valve deterioration,” noting that “reintervention after failed TEER remains a major limitation.”

Clinical Topics:
Invasive Cardiovascular Angiography and Intervention, Valvular Heart Disease, Interventions and Imaging, Interventions and Structural Heart Disease, Angiography, Nuclear Imaging

Keywords:
Transcatheter Cardiovascular Therapeutics, TCT25, Angiography, Heart Valve Diseases

Amazon is planning to cut as many as 30,000 corporate jobs beginning Tuesday, as the company works to pare expenses and compensate for overhiring during the peak demand of the pandemic, according to three people familiar with the matter.

The figure represents a small percentage of Amazon’s 1.55 million total employees, but nearly 10% of the company’s roughly 350,000 corporate employees. This would represent the largest job cut at Amazon since around 27,000 jobs were eliminated starting in late 2022.

An Amazon spokesperson declined to comment.

Amazon has been trimming smaller numbers of jobs over the past two years across multiple divisions, including devices, communications, podcasting and others.

The cuts beginning this week may impact a variety of divisions within Amazon, including human resources, known as people experience and technology, devices and services and operations, among others, the people said.

Managers of affected teams were asked to undergo training on Monday for how to communicate with staff following notifications that will start going out via email tomorrow morning, the people said.

Amazon shares were up 1.5% to $227.53. The company plans to report third quarter earnings on Thursday.

The figure represents a small percentage of Amazon’s 1.55 million total employees, but nearly 10% of the company’s roughly 350,000 corporate employees. This would represent the largest job cut at Amazon since around 27,000 jobs were eliminated starting in late 2022.

Sign up here.

An Amazon spokesperson declined to comment.

Managers of impacted teams were asked to undergo training on Monday for how to communicate with staff following notifications that will start going out via email on Tuesday morning, the people said.

Amazon CEO Andy Jassy is undertaking an initiative to reduce what he has described as an excess of bureaucracy at the company, including by reducing the number of managers. He installed an anonymous complaint line for identifying inefficiencies that has elicited some 1,500 responses and over 450 process changes, he said earlier this year.

The full scope of this round of job cuts was not immediately clear. The people familiar with the matter said the number could change over time, as Amazon’s financial priorities shift. Fortune earlier reported that the human resources division could be targeted with a cut of roughly 15%.

Amazon shares were up 1.2% at $226.80 on Monday afternoon. The company plans to report third-quarter earnings on Thursday.

Our Standards: The Thomson Reuters Trust Principles., opens new tab

By Karen Brettell

(Reuters) -The U.S. dollar weakened against the euro, Chinese yuan and Australian dollar on Monday as optimism over a possible U.S.-China trade deal boosted risk appetite and reduced demand for the greenback.

Overall moves in the currency markets were relatively muted as traders also waited on several key central bank meetings this week.

U.S. President Donald Trump said on Monday the United States and China were set to “come away” with a trade deal. Trump is expected to meet Chinese President Xi Jinping this week in South Korea.

“The market’s kind of euphoric,” said Marc Chandler, chief market strategist at Bannockburn Global Forex in New York, noting strong gains in global stock markets while gold fell.

The markets are cheered by three main developments, Chandler said.

“It looks like the U.S. and China moved away from the brink. The U.S. struck foreign trade deals or frameworks with some East Asian countries, and Milei did better in Argentina,” Chandler said, referring to the president of the South American country.

Argentine President Javier Milei’s party cruised to victory in midterm legislative elections as voters handed him a mandate to keep pushing through his overhaul of the economy.

The dollar index was last down 0.11% at 98.84, with the euro up 0.15% at $1.1643.

Central banks may dominate market direction later this week, with the Federal Reserve and Bank of Canada expected to cut rates on Wednesday, while the European Central Bank and Bank of Japan on Thursday are likely to leave rates unchanged.

With a 25-basis-point Fed rate cut long priced in, markets will closely watch for any signs that the central bank may be preparing to wind down its quantitative tightening program.

The Chinese yuan was also boosted by the People’s Bank of China setting the official yuan midpoint rate higher than expected. Prior to the market open, it set the official yuan midpoint rate at 7.0881 per dollar, the strongest since October 15, 2024, and above a Reuters estimate of 7.1146.

Chris Turner, global head of forex research at ING, said in a report that the move may be a gesture of goodwill ahead of Thursday’s Trump-Xi meeting, or a sign that China wants to boost its domestic demand.

“Either way, a stronger renminbi is normally supportive for global EM (emerging market) currencies and a mild dollar negative,” Turner said.

The Chinese offshore yuan rose to a more than one-month high against the dollar of 7.1015.

The Australian dollar was last up 0.63% versus the greenback at $0.6554. The Australian currency was also boosted by relatively hawkish comments from the country’s central bank head.

Reserve Bank of Australia Governor Michele Bullock said on Monday a rise in core inflation of 0.9% in the third quarter would be a “material miss” to forecasts that would have to be weighed by the board when judging whether to cut interest rates next week.

Traders are also focused on a meeting on Tuesday between Trump and Japan’s new Prime Minister Sanae Takaichi, where the two leaders will discuss trade issues.

The Japanese currency has weakened in recent weeks on concerns that Takaichi will implement more expansionary fiscal policies.

Against the Japanese yen, the dollar was roughly flat on the day at 152.92 yen.

Investors are further watching for any indication on when the U.S. federal government will reopen, with the U.S. economy expected to take a bigger hit the longer the shutdown goes on.

Air travel turmoil deepened with more than 2,700 flights delayed nationwide on Monday and more than 8,600 delays on Sunday, with air traffic controller absences surging amid a federal government shutdown now in its 27th day.

In cryptocurrencies, bitcoin gained 1.82% to $115,454.

(Reporting by Karen Brettell; Additional reporting by Stefano Rebaudo. Editing by Muralikumar Anantharaman, Mark Potter, Will Dunham, Andrew Heavens and Aurora Ellis)

A new AI-powered tool that lets online shoppers “be their own detective” and spot the warning signs of scams has won praise from the UK’s fraud minister.

Scam Intelligence lets customers of the digital bank Starling upload images of items and ads on online marketplaces such as Facebook Marketplace, eBay, Vinted and Etsy, which it analyses for signs of fraud before serving up personalised advice “in seconds”.

Lord Hanson, the UK’s minister for fraud, told the Guardian that the “UK-first” tool launched by the bank was “a brilliant example of how industry can deploy AI to help us stay one step ahead of fraudsters”.

Scam Intelligence was built using Gemini, Google’s AI chatbot, in collaboration with Google Cloud, and was due to be unveiled at a fintech event in Las Vegas on Monday.

During testing it increased the rate at which customers cancelled payments by 300% – suggesting it has encouraged customers to pause and reflect before making a purchase.

The launch comes days after official figures revealed that the amounts of money lost to purchase scams have hit their highest level since the banking body UK Finance started collecting data in 2020.

With these scams, the victim pays in advance for goods or services – ranging from concert tickets and cars to mobile phones and holidays – that either do not exist or never arrive. This type of fraud usually involves the victim using an online platform such as an auction website or responding to a social media advert, said UK Finance.

Using Scam Intelligence, people can upload listings and messages from sellers on online marketplaces as well as images of items for sale. The tool can also analyse screenshots of texts and messages from potential scammers that are asking customers to transfer money.

If someone is trying to buy a bike on Facebook Marketplace, the tool might inform them that “we found some risks” – which might be that the price looks too good to be true, the photos are “generic or low-quality”, which means they could be stolen or fake, or the bank account details do not match the seller’s details. If a customer is trying to buy a guitar on eBay, it might flag the seller’s refusal to use eBay’s secure payment features. Similarly, if customers receive requests to transfer money before seeing an item in person, the tool could detect “pressure and urgency tactics”.

Armed with this intelligence, customers can then decide whether to continue with the purchase or not.

Harriet Rees, the chief information officer at Starling, said its new tool would help people “to spot the signs of scams themselves” and “be their own detective and investigator”.

The bank indicated it believed the tool would be able to spot 90% of the “scam indicators” in an image.

It said that during testing, customers had tended to use it most for lower-value online marketplace items such as event tickets and trainers.

Starling said this was the first time a UK bank had offered an AI-powered scam detection tool in its app.

Customers have to opt in to take advantage of Scam Intelligence, and use of the tool is not mandatory.